Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 15 May 2024
An irreversible cognitive decline known as "chemo brain" plagues far too many cancer survivors during and after treatment. ".
Read Full NewsHere's some of what is coming soon to NeurologyLive® this week.
In a discrete choice experiment, somnolence risk and short-term efficacy were the top factors driving vesicular monoamine transporter 2 inhibitor selection for tardive dyskinesia in patients aged 55 years and older.
FDA approves once-daily oral tavapadon for Parkinson disease, a first-in-class D1/D5 partial agonist that improves motor function and ON time, with key safety warnings.
New PREVAIL trial analyses presented at the 2026 AANEM Annual Meeting showed gefurulimab reduced gMG-related hospitalizations and produced durable symptom and quality-of-life gains through one year.
PridCor Therapeutics is moving its phase 2 SHIELD trial of a combination antiviral regimen toward enrollment, building on case series data showing durable symptom improvement in long COVID.
New phase 3 MINT trial analyses presented at the 2026 AANEM Annual Meeting showed inebilizumab produced sustained improvement in MuSK-positive gMG regardless of time since diagnosis.
A joint ESC/ERA guideline on universal CKD screening headlines August 2026's nephrology news, alongside new finerenone and sibeprenlimab trial data.
1.
La FDA ha approvato Talzenna per trattare il cancro alla prostata metastatico che non è resistente alla castrazione.
2.
King Charles' Cancer; COVID Vax Now or Later; Was RFK Jr. a Drug Dealer?
3.
Annual Cancer Report Highlights Advances, Funding Threats
4.
'Significant Milestone' for Radionuclide Therapy in Refractory Meningioma
5.
Prostate cancer Q&A: Improving detection and reducing overtreatment
1.
Early Diagnosis of Lung Cancer Through Emerging Biomarkers
2.
Comprehensive Developments in Hematology in Daily Practice
3.
Understanding Evans Syndrome: Causes, Symptoms, and Treatment Options
4.
The Genetics of Bernard Soulier Syndrome: What We Know so Far
5.
Living Well After Cancer: Building Long-Term Personal Resilience
1.
International Cancer Conference
2.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
3.
International Cancer Conference
1.
Evolution in Treatment and Diagnosis of Lung Cancer- An Initiative from Manipal Hospitals
2.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part II
3.
Navigating the Brain Barrier: The CNS Challenge in ALK+ NSCLC
4.
Treatment Sequencing Strategies in ALK + NSCLC Patients with CNS Diseases
5.
Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Lenalidomide and Dexamethasone (Rd) in MRD Negativity
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge